Fresnillo Saló, S.; Schuhmacher, J.; Rahbech, A.; Pedersen, S.R.; Seremet, T.; Matillas, V.A.; Schöllhorn, A.; Røder, A.; Jørgensen, S.W.; Brasso, K.;
et al. Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial. Vaccines 2025, 13, 390.
https://doi.org/10.3390/vaccines13040390
AMA Style
Fresnillo Saló S, Schuhmacher J, Rahbech A, Pedersen SR, Seremet T, Matillas VA, Schöllhorn A, Røder A, Jørgensen SW, Brasso K,
et al. Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial. Vaccines. 2025; 13(4):390.
https://doi.org/10.3390/vaccines13040390
Chicago/Turabian Style
Fresnillo Saló, Sara, Juliane Schuhmacher, Anne Rahbech, Sara Ram Pedersen, Tina Seremet, Valero Andreu Matillas, Anna Schöllhorn, Andreas Røder, Steffen Wad Jørgensen, Klaus Brasso,
and et al. 2025. "Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial" Vaccines 13, no. 4: 390.
https://doi.org/10.3390/vaccines13040390
APA Style
Fresnillo Saló, S., Schuhmacher, J., Rahbech, A., Pedersen, S. R., Seremet, T., Matillas, V. A., Schöllhorn, A., Røder, A., Jørgensen, S. W., Brasso, K., Gouttefangeas, C., Straten, P. t., & on behalf of the RhoVac-002 Study Group.
(2025). Vaccination Against RhoC in Prostate Cancer Patients Induces Potent and Long-Lasting CD4+ T Cell Responses with Cytolytic Potential in the Absence of Clinical Efficacy: A Randomized Phase II Trial. Vaccines, 13(4), 390.
https://doi.org/10.3390/vaccines13040390
